Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 04, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
August 03, 2023 07:30 ET
|
Intra-Cellular Therapies Inc.
Q2 2023 total revenues increased to $110.8 million, compared to $55.6 million in the same period in 2022 CAPLYTA Q2 2023 net product sales were $110.1 million, compared to $55.1 million for...
Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast
July 28, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
May 31, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023 07:30 ET
|
Intra-Cellular Therapies Inc.
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in...
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
May 02, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
April 26, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features
March 28, 2023 07:00 ET
|
Intra-Cellular Therapies Inc.
Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale (MADRS) for each patient population including: -combined...